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General scientific guidance for stakeholders on health 
claim applications 
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Abstract 
The European Food Safety Authority (EFSA) asked the Panel on Dietetic Products Nutrition and 
Allergies (NDA) to update the General guidance for stakeholders on the evaluation of Article 13.1, 
13.5 and 14 health claims published in March 2011. Since then, the NDA Panel has completed the 
evaluation of Article 13.1 claims except for claims put on hold by the European Commission, and has 
evaluated additional health claim applications submitted pursuant to Articles 13.5, 14 and also 19. In 
addition, comments received from stakeholders indicate that general issues that are common to all 
health claims need to be further clarified and addressed. This guidance document aims to explain the 
general scientific principles applied by the NDA Panel for the evaluation of all health claims and 
outlines a series of steps for the compilation of applications. The general guidance document 
represents the views of the NDA Panel based on the experience gained to date with the evaluation of 
health claims, and it may be further updated, as appropriate, when additional issues are addressed.  
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Summary 
The European Food Safety Authority (EFSA) asked the Panel on Dietetic Products Nutrition and 
Allergies (NDA) to update the General guidance for stakeholders on the evaluation of Article 13.1, 
13.5 and 14 health claims published in March 2011. 
Since then, the NDA Panel has completed the evaluation of Article 13.1 claims (except for claims put 
on hold by the European Commission), and has evaluated additional health claim applications 
submitted pursuant to Articles 13.5, 14 and also 19. In addition, comments received from 
stakeholders indicate that general issues that are common to all health claims need to be further 
clarified and addressed. 
This guidance document aims to explain the general scientific principles applied by the NDA Panel for 
the evaluation of all health claims and outlines a series of steps for the compilation of applications.  
Once it is adopted, it will supersede the General guidance for stakeholders on the evaluation of Article 
13.1, 13.5 and 14 health claims and the presubmission guidance on administrative and procedural 
questions for applicants intending to submit applications for authorisation of health claims made on 
foods.  
The guidance document was subject to public consultation (from 17 July to 11 September 2015). The 
general guidance document represents the views of the NDA Panel based on the experience gained to 
date with the evaluation of health claims, and it may be further updated, as appropriate, when 
additional issues are addressed.   
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Background and Terms of Reference as provided by EFSA  
Background 
Regulation (EC) No 1924/20061 harmonises the provisions related to nutrition and health claims and 
establishes rules governing the Community authorisation of health claims made on foods. According to 
the Regulation, health claims should be only authorised for use in the Community after a scientific 
assessment of the highest possible standard to be carried out by the European Food Safety Authority 
(EFSA). 
Owing to the scientific and technical complexity of health claims, the EFSA Panel on Dietetic products, 
Nutrition and Allergies (NDA Panel) has placed considerable focus on developing scientific criteria for 
substantiation of health claims and has published guidance documents on the scientific substantiation 
of health claims since 2007.2 
Based on experience gained with the evaluation of health claims and taking into account outcomes of 
public consultation (EFSA NDA Panel, 2015), it is noted that general issues that are common to all 
health claims (e.g. general principles, administrative and procedural aspects related to the health 
claim evaluation process) need to be further clarified and addressed in the general guidance 
document for stakeholders to assist applicants in preparing and submitting their applications for the 
scientific evaluation of health claims. 
To this end, the NDA Panel is asked to update the General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims (EFSA NDA Panel, 2011a). 
Terms of reference 
The NDA Panel is requested by EFSA to update the General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. 
The guidance document shall clarify and address general issues that are common to all health claims 
(i.e. pursuant to Articles 13.1, 13.5, 14 and 19 of Regulation (EC) No 1924/2006), taking into account 
the experience gained with the evaluation of health claims by the NDA Panel including outcomes of 
public consultation. 
The draft guidance shall be released for public consultation prior to finalisation. 
Before the adoption of the guidance document by the NDA Panel, the draft guidance needs to be 
revised taking into account the comments received during the public consultation. 
A technical report on the outcome of the public consultation on the guidance document shall be 
published.  
                                                          
1  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health 
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. 
2  http://www.efsa.europa.eu/en/nda/ndaclaims.htm 
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Assessment 
1. Introduction  
The general guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims, 
published in March 2011 (EFSA NDA Panel, 2011a), laid down the general principles applied by the 
European Food Safety Authority (EFSA) Panel on Dietetic products, Nutrition and Allergies (NDA Panel) 
for the evaluation of health claims and was based on the experience gained by the NDA Panel from 
earlier evaluations. 
Since then, the NDA Panel has completed the evaluation of Article 13.1 claims (except for claims put 
on hold by the European Commission), and has evaluated additional health claim applications 
submitted pursuant to Articles 13.5, 14 and also 19. In addition, comments received from 
stakeholders during public consultations on guidance documents for health claims on specific areas 
(EFSA NDA Panel, 2015), during stakeholder meetings, and by email through the EFSA’s Application 
Desk, indicate that an update on general issues that are common to all health claims is needed.  
This guidance document aims to explain the general scientific principles applied by the NDA Panel for 
the evaluation of all health claims and outlines a series of steps for the compilation of applications. 
The draft guidance was discussed and endorsed at the NDA Plenary meeting on 30 June 2015 for 
release for public consultation. Once adopted, it will supersede the guidance published in 2011 (EFSA 
NDA Panel, 2011a), and the presubmission guidance for applicants published in 2007.3  
2. Objectives and scope 
This guidance is intended to assist applicants in preparing applications for the authorisation of health 
claims (pursuant to Articles 13.5, 14 and 19 of Regulation (EC) No 1924/2006) through an 
understanding of:  
a) the general principles which have been applied by the NDA Panel for the scientific evaluation 
of health claim applications; 
b) the issues which should be considered by applicants for the compilation of applications.  
Examples drawn from previous and ongoing evaluations are used in this guidance to illustrate the 
approach of the NDA Panel in the evaluation of health claims. A better understanding of this approach 
could help applicants in preparing health claim applications.  
This document does not intend to cover health claims which have not been evaluated by the Panel, or 
provide detailed advice on claims made in specific areas. It is also not within the scope of this 
guidance to provide detailed instructions on the design of scientific studies or on the statistical 
analyses of the results, which rely on general scientific knowledge. It is the responsibility of the 
applicant to ensure that studies are designed and performed according to scientific standards that are 
generally accepted by experts in the relevant field, and that they are appropriately reported following, 
where applicable, EFSA guidelines on statistical reporting (EFSA NDA Panel, 2014a), or other 
consensus guidelines published by scientific bodies.4 It is intended that the guidance will be kept 
under review and will be amended and updated as appropriate in the light of experiences gained from 
evaluation of additional health claim applications. 
This guidance should be read in conjunction with the scientific and technical guidance for the 
preparation and presentation of an application for authorisation of a health claim (EFSA NDA Panel, 
2011b), Regulation on Nutrition and Health Claims made on foods,5 Guidance on the implementation 
of Regulation (EC) No 1924/2006 (Standing Committee on the Food Chain and Animal Health, 2007), 
                                                          
3  http://www.efsa.europa.eu/en/ndaguidance/docs/ndapresubmissionguidance.pdf  
4   Equator network: http://www.equator-network.org/ 
5  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health 
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2006R1924:20100302:EN:PDF  
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Commission Regulation (EC) No 353/2008,6 Commission Implementing Decision of 24 January 2013,7 
and future guidelines and regulations, as applicable. 
3. Definition of terms 
In the context of this guidance document:  
 Food/constituent means a food category, a food or a food constituent (e.g. a nutrient or 
other substance, or a fixed combination of nutrients/other substances).  
 The term essential nutrient is used to denote a substance required for normal human body 
function(s) and which cannot be synthesised by the body, or cannot be synthesised in 
amounts which are adequate to maintain normal body function(s), and thus must be obtained 
from a dietary source. Essential nutrients include components of carbohydrate, protein and 
fat, as well as vitamins, minerals and water. 
 A disease/disorder means a pathological process, acute or chronic, inherited or acquired, of 
known or unknown origin, having a characteristic set of signs and symptoms which are used 
for its diagnosis. The diagnosis of diseases/disorders relies on widely accepted, well-defined 
criteria (i.e. the criteria used for diagnosis are widely accepted by the medical community and 
can be verified by a physician). In this guidance document, the term disease is used to 
include diseases and disorders, which for the purpose of this guidance are considered as 
synonymous and have the same meaning. 
 The totality of the evidence describes all the studies (e.g. in humans, in animals, in vitro) 
which are taken into consideration to conclude on the substantiation of a claim (including 
studies in favour and not in favour of the claim).  
 Efficacy study refers to an intervention study (in humans, in animals) which investigates the 
relationship between the food/constituent and the claimed effect. 
 Pertinent study means a study from which scientific conclusions that are relevant to the 
substantiation of a claim (e.g. efficacy studies, bioavailability studies, studies on the 
mechanism(s) by which a food could exert the claimed effect) can be drawn. 
 Supportive evidence refers to studies/data which, on their own, are not sufficient for the 
scientific substantiation of a claim and that may be part of the totality of the evidence only if 
pertinent human studies showing an effect of the food/constituent are available. 
 The target population is the population group(s) for which health claims are intended (e.g. 
the general healthy population or specific subgroup(s) thereof). 
 The study group denotes individuals recruited for human studies which are submitted for 
the scientific substantiation of a claim. A study group is considered as representative of the 
target population for a claim when the characteristic(s) of the study subjects may not limit the 
generalisation of the results to the target population for a claim.  
 A suitable study group means a study group which is representative of the target 
population for the claim or a study group from which extrapolation of the results to the target 
population is biologically appropriate. 
                                                          
6  Commission Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation 
of health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council 
(Text with EEA relevance) (OJ L 109, 19.4.2008, p. 11): http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2008R0353:20091221:EN:PDF 
7  Commission Implementing Decision of 24 January 2013 adopting guidelines for the implementation of specific conditions for 
health claims laid down in Article 10 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council. OJ L 
22, 25.1.2013, p. 25–28. http://eur-lex.europa.eu/legal-content/EN/ALL/?uri=CELEX:32013D0063 
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4. The legal framework for the authorisation of health claims in the 
EU: who does what and when 
The process of authorisation of health claims made on food is governed by Regulation (EC) No 
1924/2006.8 Figure 1 summarises the key steps of the process, as well as the main players at each 
step. Annex A explains the administrative and procedural aspects of applications, from claim 
formulation to authorisation. 
It is the responsibility of risk managers (i.e. the European Commission and the Member States) to 
decide on whether or not a health claim falls under the scope of Regulation (EC) No 1924/2006, e.g. 
whether a health claim is/is not a medicinal claim. This responsibility includes decisions on the 
admissibility of the target population for a claim (e.g. whether or not subjects under medications can 
be the target population for health claims made on foods).  
Regulation (EC) No 1924/2006 establishes that health claims should be scientifically substantiated by 
generally accepted scientific evidence (Article 6.1), by taking into account the totality of the available 
scientific data, and by weighing the evidence (Recital 17). Health claims should only be authorised for 
use in the Community after a scientific assessment of the highest possible standard (Recital 23). 
Regulation (EC) No 1924/2006 also establishes that, in order to ensure harmonised scientific 
assessment of these claims, EFSA should carry out such assessments (Recital 23). Within this 
framework, the NDA Panel applies similar criteria for all health claims and considers whether the 
beneficial effect of a food/constituent on a function or a risk factor for disease is substantiated by 
generally accepted scientific evidence, by taking into account the totality of the available scientific 
data and, where applicable, by weighing the evidence (see Section 6). What constitutes generally 
accepted scientific evidence in the context of claims substantiation is a scientific judgement of the 
NDA Panel. It should be noted that a safety assessment is not foreseen under the framework of 
Regulation (EC) No 1924/2006. However, where relevant, the NDA Panel may recommend restrictions 
of use based on safety considerations. 
Decisions regarding the authorisation of health claims, including the final wording and the 
conditions/restrictions of use, are taken by risk managers. In order to make such decisions, risk 
managers may take into account other legitimate factors, such as safety aspects (e.g. to modify the 
conditions/restrictions of use) or consumer understanding (e.g. to modify the wording of the claim), in 
addition to EFSA’s scientific evaluation.  
                                                          
8 http://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:02006R1924-20121129&from=EN 

































Figure 1: Key steps in the process of authorisation of health claims made on food 
Before submission




 Acknowledgement of receipt by the MS 
 Check of the application by the MS 
 MS forward the application to EFSA without delay 
 Acknowledgement of receipt by EFSA 
 Completeness check  
 Communication with the applicant for clarifications/missing 
information  
 Once the application is complete, an acceptance letter is sent to 
the applicant and the evaluation starts 
 EFSA informs/makes the application available to the 
Commission/MSs 
 The application status is published (including the summary of the 
application, where applicable) 
 Read this guidance and other EFSA guidance documents 
 Formulation of the claim 
 Has a similar claim been evaluated/authorised? 
 Is the claim an Article 13(5), 14(1)(a), 14(1)(b), or 19? 
 Check on the scope and admissibility of the target population 
 Preparation of the application   
EFSA opinion adopted
Guidance and Section 8
Check EFSA opinions/EU 
Register
Contact MS  
Sections 4, Annex A  
Guidance and Annex A
Contact MS. Annex A 
Annex A
EFSA Register of questions
 Elaboration/discussion of the draft opinion by the WG on Claims 
 EFSA may request clarification/additional information to the 
applicant (stop-the-clock procedure) 
 Submission of the draft opinion to the Panel for discussion/adoption 
 EFSA has 5 months to deliver its opinion (excluding stop-the-clock 
time) 
 Application withdrawal is only possible before adoption of the 
opinion by the Panel 
Sections 6, 7
Annex A  
Clarification: teleconference or 
technical hearing, if needed 
Clarification: teleconference, if 
needed 
 Notification of the adoption to the applicant one working day after 
adoption of the opinion  
 Notification of the opinion to the applicant one working day before 




Contact EC  
Annex A
 Authorised claim, including the final wording and the 
conditions/restrictions of use, is published  
 Comments on the EFSA opinion should be sent to the Commission 
within 30 days after publication.  
 Post-adoption meeting with applicants (if requested) 
 Applicants can discuss the final wording of claims with the 
Commission (consumer understanding)  
Check EU Register
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5. Scientific standards vs regulatory requirements 
Article 7(3) of Regulation (EU) No 1169/20119 states: food information to consumers shall not 
attribute to any food the property of preventing, treating or curing a human disease, nor refer to such 
properties. In addition, Article 2(6) of Regulation (EC) No 1924/2006 defines a ‘reduction of disease 
risk claim’ as any health claim that states, suggests or implies that the consumption of a food 
category, a food or one of its constituents significantly reduces a risk factor in the development of a 
human disease. The Regulation, therefore, indicates that, for the purpose of communicating the 
health properties of a food/constituent to consumers: 
a) subjects with a disease cannot be the target population for health claims made on food. Thus, in 
principle, the target population for health claims made on food should be the general (healthy) 
population or specific subgroups thereof;  
b) function claims cannot refer to a disease; 
c) disease risk reduction claims cannot refer to the reduction of the risk of a disease, but should refer 
to the reduction of a risk factor for disease;10   
However, stakeholders have noted that this regulatory framework may be in contradiction to some 
basic scientific principles which have governed the assessment of the relationship between 
food/constituents and health, such as: 
a) several studies investigating whether or not, and how, a food/constituent exerts a beneficial effect 
on a function have been conducted in subjects meeting the diagnostic criteria for a disease which 
negatively affects such function. In addition, the first-line therapy for patients with diet-related chronic 
diseases (e.g. obesity, type 2 diabetes, hypertension) is often dietary advice, and thus they could 
benefit the most from health claims made on foods; 
b) in some cases, the relationship between a food/constituent and a function can be best measured 
by using disease outcomes;11  
c) with respect to the likelihood that the consumption of a food/constituent would effectively modify 
the risk of the disease, disease outcomes provide stronger evidence than risk factors for disease. In 
addition, in some circumstances it may be easier to measure disease outcomes than risk factors for 
disease.12 
In order to fill the gap between the above-mentioned scientific principles and regulatory requirements, 
the NDA Panel has worked with applicants during the evaluation of applications on the formulation of 
health claims which could allow a scientific evaluation with the type of human studies provided but 
also comply with the requirements of Regulation (EU) No 1169/2011, as follows:  
a) studies conducted in subjects with a disease may be used to substantiate function claims for the 
general population or subgroups thereof (without the disease) as long as the effect of the 
food/constituent on the body function which is named in the claim is expected to occur in subjects 
without the disease and a rationale is given for such expectations13 (see Section 7.6).  
                                                          
9  Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food 
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and 
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 
1999/10/EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 
2008/5/EC and Commission Regulation (EC) No 608/2004. J L 304, 22.11.2011, p. 18–63. http://eur-lex.europa.eu/legal-
content/EN/TXT/PDF/?uri=CELEX:32011R1169&from=EN  
10 For example, claims on the reduction of the risk for coronary heart disease (CHD) cannot be made, but they must refer to the 
reduction of a risk factor for CHD (e.g. LDL-cholesterol, blood pressure). 
11 For example, the effect of a food/constituent on cardiac function can be measured by its effects on CHD disease outcomes 
http://www.efsa.europa.eu/en/efsajournal/doc/1796.pdf 
12 For example, it may be easier to assess the incidence/severity/duration of lower urinary tract infections than the inhibition of 
bacterial adhesion to the bladder wall in vivo in humans. 
13 For example, studies in obese subjects could be used to substantiate a claim on the reduction of body weight addressed to 
overweight adults http://www.efsa.europa.eu/en/search/doc/1798.pdf, whereas studies on subjects with arthritis of various 
origins (rheumatoid arthritis, psoriatic arthritis, arthritis of infectious origin) and which relate to the treatment of symptoms of 
the disease cannot be considered for the scientific substantiation of health claims on joint function for the general population. 
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b) longitudinal (observational and intervention) studies on the relationship between a food/constituent 
and the incidence14 of disease in subjects free of disease at recruitment may be used to substantiate 
claims on a function which affects the development of the disease.15  
c) studies on the relationship between a food/constituent and the incidence16 of disease in subjects 
free of disease at recruitment may also be used to substantiate disease risk reduction claims17 (see 
Section 7.2.2).  
6. General principles applied by the Panel to decide whether a health 
claim is substantiated 
The general principles applied by the NDA Panel for the assessment of claims based on the 
essentiality of nutrients differ from those applied for the assessment of other claims. Such differences 
refer to the requirements for the definition of the claimed effect (Section 7.2), for the scientific 
substantiation of the claim (Section 6.1) and for establishing conditions of use (Section 7.9).  
6.1. Claims based on the essentiality of nutrients  
The essentiality of a nutrient is determined by knowledge of its unique ability to reverse clinical signs 
and symptoms of deficiency, and/or by knowledge of its essential mechanistic role in metabolic 
functions. The recognition by the scientific community of the essentiality of individual nutrients first 
took place in the early decades of the last century and is based on a large body of scientific evidence, 
which includes case reports of clinical signs and symptoms of deficiency (e.g. during long-term total 
parenteral nutrition), depletion–repletion studies in humans, invasive animal studies and meticulous in 
vitro studies, among other evidence.  
In this context, information about the essentiality of nutrients cannot be obtained from randomised 
controlled trials (RCTs), which are at the top of the hierarchy of evidence for the scientific 
substantiation of health claims for two reasons: i) RCTs in most nutrient-deficient subjects are 
unethical, and ii) RCTs in nutrient-replete subjects are unsuitable because the body functions for 
which the nutrient is required will not be modified by higher intakes (EFSA NDA Panel, 2009a).18 
For the scientific substantiation of claims based on the essentiality of nutrients, the Panel considers 
the following well-established scientific principles: 
i. the nutrient is required for normal human body function(s), i.e. it has an essential mechanistic 
role in a metabolic function and/or it has the ability to reverse clinical signs and symptoms of 
its deficiency; 
ii. the nutrient cannot be synthesised by the body, or cannot be synthesised in amounts which 
are adequate to maintain normal body function(s); 
iii. the nutrient must be obtained from a dietary source.  
Only claims which meet the above-mentioned requirements on the relationship between the 
consumption of a nutrient and human body function(s) have been considered by the Panel as claims 
based on the essentiality of nutrients. The scientific substantiation of these claims has been based on 
a large body of scientific evidence which led to the recognition of the essentiality of a particular 
                                                          
14 Severity and duration of the disease can also be considered for acute disease states which generally resolve, such as acute 
infections or allergic reactions. 
15 For example, studies on the incidence of dental caries can be used to substantiate claims on the maintenance of normal tooth 
mineralisation. 
16 Severity and duration of the disease can also be considered for acute disease states which generally resolve, such as acute 
infections or allergic reactions. 
17 For example, evidence that a food/constituent decreases the risk of lower urinary tract infections could be used for the 
substantiation of disease risk reduction claim. In this context, evidence that the food/constituent decreases bacterial adhesion 
in vitro could be used as a risk factor in the wording of the claims (as required by Regulation (EU) No 1169/2011) because it 
may be plausibly involved in the pathogenesis of the disease, and in this case evidence that the modification of in vitro 
bacterial adhesion also modifies the incidence of the disease is not required.  
18 A claim on vitamin C and function of the immune system intended for the general population (ID134) was based on the 
essentiality of vitamin C for the function, whereas a claim in vitamin C and function of the immune system during and after 
extreme physical exercise (ID 144)  was substantiated on the basis of RCTs showing a reduction in the severity/duration of 
common cold in the target population, and thus was not based on the essentiality of vitamin C for the function: 
http://www.efsa.europa.eu/en/efsajournal/pub/1226  
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nutrient with respect to one or more body functions. For these claims, the NDA Panel did not review 
the primary scientific studies submitted and did not weigh the evidence. 
These claims will not be discussed further in this guidance, except in Sections 7.2 (characterisation of 
the claimed effect) and 7.9 (conditions of use). 
6.2. Claims other than those based on the essentiality of nutrients 
For the scientific substantiation of a claim, the NDA Panel considers the totality of the available 
scientific evidence. It is the responsibility of the applicant to provide these data. In its assessment, the 
NDA Panel may use data which are not included in the application if such data are considered 
pertinent to the claim.  
In assessing each specific food/health relationship which forms the basis of a claim, the NDA Panel 
makes a scientific judgement on the extent to which a cause and effect is established between the 
consumption of the food/constituent and the claimed effect (i.e. for the target group under the 
proposed conditions of use) by considering the strength, consistency, specificity, dose–response, 
biological plausibility of the relationship and by weighing the totality of the evidence. A grade is not 
assigned to the evidence. 
Pertinent human (intervention and observational) studies are central for health claim substantiation. 
Pertinent human intervention studies are at the top of the hierarchy that informs decisions on 
substantiation because it is of utmost importance to show that the food/constituent can exert the 
claimed effect in humans and that the effect is specific for the food/constituent, an information which 
can only be obtained from human intervention studies (EFSA NDA Panel, 2011b). Human intervention 
(and observational) studies can also provide evidence for a dose–response relationship and for 
consistency of the effect (or the association) across studies. Efficacy studies in animals and non-
efficacy studies in humans, animals and/or in vitro (e.g. evidence for a mechanism by which a food 
could exert the claimed effect) may be part of the totality of the evidence only if pertinent human 
studies showing an effect of the food/constituent are available.19 
The outcome of each assessment is one of three possible conclusions:  
i. A cause and effect relationship has been established between the consumption of the 
food/constituent and the claimed effect.  
The NDA Panel considers that the evidence provided is convincing and sufficient for a positive 
outcome.  
ii. The evidence provided is insufficient to establish a cause and effect relationship between the 
consumption of the food/constituent and the claimed effect.  
The Panel considers that, although there is some evidence in favour of the claim, such evidence is 
neither convincing nor sufficient for a positive outcome. 
iii. A cause and effect relationship has not been established between the consumption of the 
food/constituent and the claimed effect.  
The NDA Panel considers that there is no, or at most very limited, scientific evidence in favour of the 
claim. 
                                                          
19 For example, in an application related to monacolin K from red yeast rice and maintenance of normal blood LDL-cholesterol 
concentrations (http://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/2304.pdf), the Panel 
took into consideration the results of an in vitro study showing that a fermented red yeast rice preparation (Cholestin) had an 
inhibitory effect on HMG-CoA reductase activity in human hepatic cells to support the mechanism by which monacolin K from 
red yeast rice could exert the claimed effect. Another example on how animal and in vitro studies can support the effect and 
mechanism of action of the food/constituent in humans comes from an application related to water-soluble tomato 
concentrate (WSTC I and II) and platelet aggregation (http://www.efsa.europa.eu/sites/default/files/
scientific_output/files/main_documents/1101.pdf). In that case, the Panel considered the results of four in vitro studies and 
of one animal study for the biological plausibility of the effect observed in human studies. 
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7. Main issues addressed by the NDA Panel for the evaluation of 
health claims 
In assessing each specific food/health relationship which forms the basis of a health claim the NDA 
Panel considers the following key questions:  
(i) the food/constituent is defined and characterised (Section 7.1);  
(ii) the claimed effect is based on the essentiality of a nutrient; OR  
the claimed effect is defined and is a beneficial physiological effect for the target 
population, and can be measured in vivo in humans (Section 7.2);   
(iii) a cause and effect relationship is established between the consumption of the 
food/constituent and the claimed effect (for the target group under the proposed 
conditions of use) (Sections 7.3 and 7.4). 
Each of these three questions needs to be assessed by the NDA Panel with a favourable outcome for a 
claim to be substantiated. In addition, an unfavourable outcome of the assessment of questions (i) 
and/or (ii) precludes the scientific assessment of question (iii).  
If a cause and effect relationship is considered to be established, the NDA Panel considers whether:  
 the proposed wording reflects the scientific evidence (Section 7.8);  
 the proposed wording complies with the criteria for the use of claims specified in the 
Regulation (Section 7.8); 
 the quantity of food/pattern of consumption required to obtain the claimed effect can 
reasonably be consumed within a balanced diet (Section 7.9);  
 the proposed conditions/restrictions of use are appropriate (Section 7.9); 
 the data claimed as proprietary by the applicant were needed to reach the conclusion (Annex 
A.4).  
7.1. Characterisation of the food/constituent 
7.1.1. Extent to which a food/constituent should be characterised 
The NDA Panel considers whether the information provided in relation to the food/constituent includes 
those characteristics which may influence the specific physiological effect that is the basis of the 
claim. Such characteristics may depend on the nature of the food constituent, but also on the specific 
claimed effect.  
It may be necessary to distinguish between a specific constituent, a combination of constituents, or a 
specific formulation. The following cases have been identified by the Panel: 
 If the claim is for an individual constituent, the source and specifications (e.g. physical and 
chemical properties) should be provided. Characterisation of essential nutrients would relate 
mainly to the chemical form of the nutrient naturally present in foods and forms that are 
approved for addition to foods.20 
 If the claim is for a specific formulation or a fixed combination of constituents, then studies 
are needed on the specific formulation or combination, whereas studies on the individual 
constituents or combinations of constituents other than the combination for which the claim is 
proposed are not required. However, if individual constituent(s) in the specific formulation 
have an established role on the claimed effect (e.g. evidence for their role on the claimed 
effect has been already evaluated by the Panel with a positive outcome), the NDA Panel also 
considers whether: i) the effect could be explained by the individual constituent(s), regardless 
of the source; ii) other constituent(s) in the specific formulation are required for/contribute to 
                                                          
20  Commission Regulation (EC) No 1170/2009 of 30 November 2009 amending Directive 2002/46/EC of the European 
Parliament and of Council and Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards the 
lists of vitamin and minerals and their forms that can be added to foods, including food supplements. OJ L 314, 1.12.2009, p. 
36–42. 
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the claimed effect (i.e. whether the specific formulation has an effect beyond what could be 
expected from the presence of the individual constituent(s) with an established role on the 
claimed effect21).   
 For a food category (e.g. ‘dairy products’ (EFSA NDA Panel, 2011c)), the NDA Panel considers 
whether the information provided sufficiently addresses the variability between individual 
foods regarding those characteristics which may influence the specific claimed effect.  
 For plant products (EFSA Scientific Committee, 2009), the NDA Panel considers whether the 
information provided includes the scientific (latin) name (full systematic species, name 
including botanical family, genus, species, variety, subspecies, author’s name and chemotype, 
where relevant; e.g. Punica granatum L, Lythraceae (Punicaceae)), the part used (e.g. fruit, 
root, leaf, seed), complete specifications of the manufacturing process (e.g. dried, 
hydroalcoholic extraction, plant extract ratio) and how the product is standardised (e.g. by its 
content of one or more specific constituents).  
 For microorganisms (e.g. bacteria and yeast), the NDA Panel considers whether, in addition to 
species identification, sufficient information is provided for characterisation (genetic typing) at 
strain level by internationally accepted molecular methods, and the naming of strains 
according to the International Code of Nomenclature.22 In the case of a combination of two or 
more microorganisms, the Panel considers that if one of the microorganisms used in the 
combination is not sufficiently characterised, the combination proposed is also not sufficiently 
characterised (see Annex B for characterisation of microorganisms at strain level).  
 For comparative claims, both the food/constituent that is the subject of the claim and the 
comparator, or the food/constituent it should replace in foods in order to obtain the claimed 
effect, should be sufficiently characterised for a scientific evaluation with respect to the 
factors which may have an impact on the claimed effect. Applicants should take into account 
the Commission guidance on the implementation of Regulation (EC) No 1924/2006, of 
December 2007 for the use of comparative claims (Standing Committee on the Food Chain 
and Animal Health, 2007).  
The NDA Panel also considers whether the specific food/constituent is sufficiently characterised in 
order to: 
(i) establish that the studies submitted for the substantiation of the claim were performed 
with a food/constituent which complies with the specifications given for the food/constituent 
for which the claim is proposed (e.g. the microbial strain(s) used). Sufficient characterisation 
would allow control authorities to verify that the food/constituent which bears a claim is the 
same as that which was the subject of a Community authorisation; 
(ii) define appropriate conditions of use for the claim.  
It is the responsibility of the applicant to provide this information along with information regarding the 
manufacturing process and stability of the food/constituent, where applicable, in order to show 
consistency in the final product for those characteristics considered to influence the specific claimed 
effect.  
7.1.2. Contexts in which a food/constituent could be characterised in relation to 
the claimed effect 
In principle, food/constituents cannot be characterised on the basis of the claimed effect (e.g. non-
cariogenic carbohydrates, antioxidant foods, microorganisms which contribute to the defence against 
pathogens in the respiratory tract).  
                                                          
21  E.g. whether the consumption of soy lecithin preparations (in which phosphatidyl cholines are the most abundant 
phospholipid) has an effect on blood cholesterol concentrations beyond what could be expected from their content of linoleic 
acid: http://www.efsa.europa.eu/en/scdocs/doc/1741.pdf   
22  The approved nomenclature for bacteria is kept at the International Committee on Systematics of Prokaryotes for 
(http://icsp.org/), and the International Code of Nomenclature of fungi is kept by the International Commission on the 
Taxonomy of Fungi (ICTF) (www.fungaltaxonomy.org) and the approved nomenclature for fungi can also be found on the 
MycoBank (http://www.mycobank.org).    




www.efsa.europa.eu/efsajournal 15 EFSA Journal 2016;14(1):4367 
 
However, in specific circumstances, the food/constituent(s) could be characterised on the basis of a 
property which could explain their contribution to the claimed effect (i.e. when the mechanism by 
which the claimed effect is achieved is known). For example, non-digestible carbohydrates have been 
defined on the basis of a property (non-digestibility in the small intestine) which explains their 
contribution to the reduction of postprandial blood glucose responses when replacing digestible 
carbohydrates in foods (EFSA NDA Panel, 2014b); some food/constituents have been characterised on 
the basis of their α-amylase inhibitory activity, which was considered to explain their potential effect 
on body weight changes (EFSA NDA Panel, 2012a, 2014c). 
7.2. Characterisation of the claimed effect 
According to Regulation (EC) No 1924/2006, the use of health claims shall only be permitted if the 
food/constituent, for which the claim is made, has been shown to have a beneficial physiological 
effect.  
In assessing each claim, the NDA Panel makes a scientific judgement on whether the claimed effect is 
considered to be a beneficial physiological effect, as described in the information provided by the 
applicant and by taking into account the target population for which the claim is intended. In principle, 
the target population of claims made on food is the general population or subgroups thereof defined 
on the basis of age, sex, physiological conditions and/or lifestyle (e.g. children, men, postmenopausal 
women, adults performing endurance exercise). Decisions on the admissibility of a different target 
population for a claim (e.g. whether or not subjects under medications can be the target population 
for health claims made on foods) are taken by the risk managers (see Section 4) and are out of the 
scope of this guidance.  
7.2.1. Characterisation of the claimed effect for function claims 
For function claims, the beneficial physiological effect relates to the maintenance, reduced loss or 
improvement of a body function.  
For claims which are based on the essentiality of nutrients, the claimed effect can refer to general 
functions of organs, tissues or systems (i.e. does not need to be a specific function which is testable 
and measurable in vivo in humans by generally accepted methods) because symptoms of deficiency of 
a nutrient can result from broad effects on one or more organs and/systems and it is sometimes not 
possible or appropriate to single out a precise function that is affected by deficiency of that nutrient.  
For claims other than those based on the essentiality of nutrients, the NDA Panel considers whether 
the claimed effect:  
i) refers to a specific body function (i.e. it is not general and non-specific), as required by 
Regulation (EC) No 1924/2006, and whether it is sufficiently defined for a scientific evaluation. Claims 
referring to general wellbeing or unspecified functions of organs, tissues and systems are not 
considered by the NDA Panel as sufficiently defined for a scientific evaluation;23 
ii) is a beneficial physiological effect for the target population for which the claim is 
intended;24 
iii) can be assessed in vivo25 in humans by generally accepted methods. To this end, the Panel 
considers the appropriateness of the outcome variable(s) and of the methods of measurement 
proposed to assess the claimed effect in human studies.  
                                                          
23 For example, ‘gut health’, ‘natural defences’, ‘immune function’ or ‘skin health’. 
24 For example, ‘a reduction of gastric acid levels’ or ‘a reduction of inflammation’ could represent therapeutic objectives for the 
management or treatment of some disease conditions, but they are not considered by the NDA Panel as beneficial 
physiological effects for the target population (i.e. the general population or subgroups thereof). 
25 It includes the measurement of functional outcome variables in vivo and the measurement (ex vivo) of outcome variables in 
biological samples following an intervention in vivo. 
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In this context, it should be noted that:  
a) some claimed effects, which are considered as beneficial physiological effects, cannot be evaluated 
by the Panel if no generally accepted methods for the assessment of the outcome variable(s) of 
interest in vivo in humans have been provided.26   
b) changes in outcome variable(s), which can be measured in vivo in humans by generally accepted 
methods, may not be considered beneficial physiological effects per se, and thus cannot be the 
claimed effect (i.e. constitute the only basis for the scientific substantiation of a health claim).27 
Changes in such outcome variable(s) should be accompanied by evidence of a beneficial physiological 
effect or clinical outcome, and could be proposed as part of the mechanisms by which a food may 
exert the claimed effect, i.e. induce a beneficial change on a function. In certain circumstances, 
however, changes in outcome variable(s) measured in vivo in humans, and which do not refer to a 
function directly, may be the claimed effect if evidence is provided that changes in such variable(s) 
generally induce a beneficial change in a function.28  
In principle, if a body function which is the subject of the claim (e.g. maintenance of normal 
defecation) is best described by a number of outcome variables which are interrelated (e.g. stool 
frequency, stool consistency, faecal bulk and transit time), and which in combination could provide 
information about the function and eventually about the underlying mechanism of action, the Panel 
will consider the information provided on all these variables to evaluate the claim. However, the 
selection of the outcome variable(s) to be tested in a study and the decision to treat such variable(s) 
as primary or as secondary outcomes would depend, among other considerations, on the study 
objectives (e.g. exploratory, confirmatory), the outcome variable(s) on which the power calculation 
was based, the study group, and the information which is already available (in the literature, or to the 
applicant) regarding the relationship between the consumption of the food/constituent and the 
claimed effect (e.g. whether a mechanism of action by which the food/constituent could exert the 
claimed effect is already known).  
7.2.2. Characterisation of the claimed effect for reduction of disease risk claims 
For reduction of disease risk claims, the beneficial physiological effect is the reduction (or beneficial 
alteration) of a risk factor for the development of a human disease (not the reduction in the incidence 
of disease). 
Whether or not the alteration of a factor is considered by the NDA Panel to be beneficial in the 
context of a reduction of a disease risk claim depends on the extent to which it is established that:  
i) the factor is an independent predictor of the risk of disease (such a predictor may be 
established from intervention and/or observational studies); 
ii) the relationship between the factor and the development of the disease is biologically 
plausible. 
If there is evidence from intervention (drug or dietary) studies that a reduction of the risk factor 
generally reduces the incidence of disease and the involvement of the risk factor in the development 
of the disease is biologically plausible, a reduction of the risk factor is considered beneficial in the 
context of a reduction of disease risk claim. In this case, evidence that the dietary intervention with 
the specific food/constituent induces a reduction (or beneficial alteration) of the risk factor would be 
                                                          
26 An example is the lack of generally accepted methods for the measurement of the inhibition of adhesion of P-fimbriated E. 
coli to uroepithelial cells in vivo in humans, even though this particular effect was considered a beneficial physiological effect 
in a particular application for a claim on the reduction of bacterial colonisation of the urinary tract by inhibition of the 
adhesion of P-fimbriated E.coli to uroepithelial cells. The reasons for the Panel’s conclusions can be found in the published 
opinion: http://www.efsa.europa.eu/en/efsajournal/pub/3082  
27 Examples of outcome variable(s) which can be measured in vivo in humans by generally accepted methods but do not refer 
to a benefit on specific functions and thus cannot constitute the only basis for the scientific substantiation of a health claim 
include, but are not limited to, changes in macular pigment optical density, changes in stool pH and short-chain fatty acid 
production in the gut, and changes in the composition of the gut microbiota. 
28 For example, changes in skeletal muscle glycogen stores, which can be measured in vivo in humans by generally accepted 
methods but do not refer to a benefit on a function directly, can be used as an appropriate outcome variable for claims on 
the recovery of normal muscle function after strenuous exercise because evidence has been provided that changes in skeletal 
muscle glycogen stores lead to the recovery of normal skeletal muscle function after exercise: 
http://www.efsa.europa.eu/en/efsajournal/pub/3409   
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sufficient for the scientific substantiation of the claim.29 The general principles applied by the Panel to 
decide whether there is a causal relationship between a beneficial modification of the risk factor and a 
reduction of the risk of the disease (i.e. whether the risk factor for disease is well established) are the 
same (i.e. hierarchy of studies, weighing of the evidence) as the principles applied by the Panel to 
decide whether a causal relationship between the consumption of a food/constituent and the claimed 
effect is established (i.e. whether a health claim is substantiated) (see Section 6.2). 
If there is no such evidence from intervention studies that a reduction of the risk factor generally 
reduces the incidence of disease, but there is evidence for an independent association between the 
proposed risk factor and the incidence of the disease from observational studies and the involvement 
of the risk factor in the development of the disease is biologically plausible, a reduction of the risk 
factor may be considered a beneficial physiological effect in the context of a reduction of disease risk 
claim. In this case, however, evidence that the dietary intervention with the specific food/constituent 
induces a reduction (or beneficial alteration) of the risk factor and also a reduction of the risk of 
disease needs to be provided.30  
7.3. Evidence required for the scientific substantiation of health claims  
Each relationship between a food/constituent and a claimed effect is assessed by the NDA Panel 
separately on a case by case basis for specific claim applications. Pertinent human studies are an 
absolute requirement for the scientific substantiation of health claims, and pertinent human efficacy 
studies are at the top of the hierarchy that informs decisions on substantiation. However, there is no 
pre-established rule as to how many or which types of studies are needed for substantiation. The 
reproducibility of the effect of the food/constituent, as indicated by the consistency of the findings 
(within and across studies), and the biological plausibility of the effect also need to be considered.  
The scientific opinions on health claim applications evaluated by the NDA Panel with a positive 
outcome provide examples as to the number, type and quality of the studies which may be needed for 
the scientific substantiation of health claims in the context of specific applications.31 
For example, a claim on arabinoxylan and a reduction on postprandial blood glucose responses was 
substantiated on the basis of: i) a single well-designed and scientifically sound human intervention 
study showing a dose–response effect of the food/constituent in a study group which is representative 
of the target population, ii) a human study showing an effect of the food/constituent on an outcome 
variable which was only indirectly related to the claimed effect, iii) strong evidence for a plausible 
mechanism of action (EFSA NDA Panel, 2011d). Three well-designed and scientifically sound human 
intervention studies showing a consistent effect of the food/constituent across study groups which are 
representative of the target population or from which the results could be extrapolated to the general 
population were sufficient to substantiate a claim on Limicol® and reduction of blood LDL-cholesterol 
concentrations, even though no evidence for a mechanism by which the food/constituent may have 
                                                          
29  For example, it is well established that elevated blood LDL-cholesterol concentration is independently associated with an 
increased risk of coronary heart disease (CHD), and that reducing blood LDL-cholesterol concentration (by dietary 
modification or drugs) would generally reduce the risk of development of CHD. It is also well established that elevated 
(systolic) blood pressure is independently associated with an increased risk of CHD and stroke, and that reducing (systolic) 
blood pressure (by dietary modification and drugs) would generally reduce the risk of development of CHD and stroke. 
Reduction in blood LDL-cholesterol concentration, therefore, is considered beneficial in the context of a reduction of disease 
risk claim for CHD, and reduction in (systolic) blood pressure is considered beneficial in the context of a reduction of disease 
risk claim for CHD and stroke (http://www.efsa.europa.eu/en/efsajournal/pub/2474). It is also well established that falling is 
a risk factor for bone fractures in the elderly, and that reducing the risk of falling (e.g. by dietary modification, by drugs, by 
modification of architectonical barriers) reduces the risk of bone fractures (http://www.efsa.europa.eu/en/efsajournal/
pub/2382).   
30  For example, there is some evidence that low blood HDL-cholesterol concentration, elevated blood concentration of 
triglycerides, or elevated blood homocysteine concentration are associated with an increased risk of coronary heart disease 
(CHD). Reduction in blood concentration of triglycerides, reduction in blood homocysteine concentration, or an increase in 
blood HDL-cholesterol concentration, have been associated with a decreased incidence of CHD following certain dietary 
interventions in some human intervention studies. However, changes in any of these factors (by dietary modification or 
drugs) have not generally been shown to reduce the risk of CHD. Therefore, human studies on the risk of CHD are required 
for the substantiation of these disease risk reduction claims in order to validate the association between these variables and 
the risk of disease in the context of a particular nutrition intervention. http://www.efsa.europa.eu/en/efsajournal/pub/2474  
31 Examples of health claims substantiated using different types and amount of studies include, but are not limited to: 
http://www.efsa.europa.eu/en/efsajournal/pub/2809;  http://www.efsa.europa.eu/it/efsajournal/pub/1101;  
http://www.efsa.europa.eu/en/efsajournal/pub/2382; http://www.efsa.europa.eu/en/efsajournal/pub/1776; 
http://www.efsa.europa.eu/en/efsajournal/pub/1885 
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exerted the claimed effect was provided (EFSA NDA Panel, 2013). A health claim on eicosapentaenoic 
acid (EPA) and docosahexaenoic acid (DHA) and maintenance of normal cardiac function was 
substantiated on the basis of a wealth of human observational studies showing a consistent 
association between the consumption of the food/constituent and coronary heart disease outcomes in 
the target population plus human intervention studies showing an effect of the food in diseased 
subjects under medication (EFSA NDA Panel, 2010a). 
7.4. Identification of pertinent human studies 
As mentioned in the previous section, pertinent human studies are central for the scientific 
substantiation of health claims. In order to identify such studies among those submitted in an 
application, the NDA Panel evaluates:  
i) whether the food/constituent investigated in the study complies with the specifications of 
the food/constituent for which the claim is proposed; 
ii) whether the outcome variable(s) are well-defined and appropriate to assess the claimed 
effect, and whether they have been measured using valid methods; 
iii) the design and quality of the study in relation to the risk of bias;32 
iv) whether the study group is representative of the target population for the claim, or 
whether extrapolation of the results from the study group to the target population is 
scientifically plausible; 
v) how the conditions under which the study has been conducted relate to the conditions of 
use (e.g. quantity and pattern of consumption of the food/constituent) proposed for the 
claim. 
Well-designed and conducted randomised controlled trials (i.e. at low risk of bias) investigating the 
effect of a food/constituent which complies with the specifications of the food/constituent for which 
the claim is proposed on appropriate outcome variables for the claimed effect, in a suitable study 
group, and under the conditions of use proposed for the claim are at the top of the hierarchy which 
informs decisions on substantiation (EFSA NDA Panel, 2011b). In principle, the study duration should 
be adequate in order to exclude: i) adaptation to the continuous consumption of the food/constituent 
through compensatory mechanisms; ii) chance findings (e.g. for fluctuating outcome measures). The 
quality of reporting, although not inherently linked to the quality of the study, will have an impact on 
the outcome of the NDA Panel’s assessment.33 
For human studies which assess outcome variables subject to seasonal variations (e.g. respiratory 
tract infections, blood pressure), the design of the study should be such that seasonal bias is avoided 
(e.g. bias introduced by differences between the intervention and control groups regarding the 
number of subjects investigated in different seasons of the year). The period of enrolment should be 
defined accordingly. For self-reported outcome variables (i.e. symptoms), which are subjective in 
nature, adequate blinding of subjects and investigators to the intervention is particularly important. 
Specific tools, in the form of questionnaires, have been used to measure self-reported outcome 
variables(s) in human intervention studies. Considerations on the validation of questionnaires and 
their use as outcome variables for the scientific substantiation of claims are in Annex C.  
7.5. Use of meta-analyses to inform decisions on substantiation 
If a meta-analysis of human (observational and/or intervention) studies is provided for the scientific 
substantiation of a claim, the Panel reviews the primary data to ensure that all the individual studies 
included in the meta-analysis are pertinent to the claim.  
                                                          
32 Different tools to appraise the design and quality of human studies (of different designs) with respect to the risk of bias have 
been developed by different bodies and are publicly available. Although these tools are different from each other, they cover 
a common core of concepts for assessing study quality. As an indication of aspects that the Panel considers when appraising 
the quality of RCTs, see also Appendix B at: http://www.efsa.europa.eu/en/supporting/pub/836e  
33 Guidelines for adequate reporting of research studies can be found at http://www.equator-network.org and EFSA Guidance 
on Statistical Reporting: http://www.efsa.europa.eu/en/efsajournal/pub/3908  
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Meta-analysis can provide information about the reproducibility and consistency of the effect across 
studies and study groups, about the dose–response relationship, and about the minimum effective 
dose of the food/constituent which is required to obtain the claimed effect (i.e. to establish conditions 
of use). 
Information derived from meta-analyses has been used by the Panel in published opinions to 
summarise the overall evidence provided by individual human studies and to establish conditions of 
use (e.g. to define the effective dose), for example EFSA (2008) and EFSA NDA Panel (2011e). The 
NDA Panel, however, did not rely on the results of meta-analyses to make a scientific judgement on 
whether a cause and effect relationship between the consumption of the food/constituent and the 
claimed effect has been established. 
7.6. Extrapolation of the results from the study group to the target 
population  
When a particular study submitted for the scientific substantiation of the claim has been conducted in 
a study group (e.g. subjects with a disease) which is different from the target population for a claim 
(e.g. the general population or subgroups thereof), the NDA Panel considers whether the results from 
that study can be extrapolated to the target population for the claim. In principle: 
(i) results from studies performed in non-diseased subjects, including subjects at high risk for 
disease34 (e.g. women with high frequency of lower urinary tract infections (LUTI) in the 
previous year but free of LUTI at recruitment) and in whom the function targeted by the 
claim (e.g. defence against pathogens in the lower urinary tract) may be affected, could 
be extrapolated to the target population (e.g. adult women in the general population). 
However, as this decision is made by the Panel on a case-by-case basis, accurate 
information on the selection criteria used in these studies to identify and recruit subjects 
at high risk of the disease should be provided to ascertain that the subjects recruited are 
free from disease and to allow the Panel to decide whether extrapolation of the results 
from the study group to the target population is biologically appropriate. 
(ii) results from studies performed in subjects with a disease (i.e. type 2 diabetic patients) 
that affects the function mentioned in the claim (e.g. reduction of postprandial blood 
glucose responses) can be extrapolated to the target population for a claim (e.g. the 
general population) as long as the effect of the food/constituent on the beneficial 
physiological effect which is mentioned in the claim is also reasonably expected to occur 
in subjects without the disease (e.g. if it can be established that the mechanism by which 
the food/constituent exerts a beneficial effect on the disease is the same by which it could 
reduce the risk of a disease in the target population). If subjects with a disease are under 
pharmacological treatment, the Panel considers whether the effect of the food/constituent 
is also reasonably expected to occur in subjects without medication. 
(iii) results from studies performed exclusively in healthy subjects selected on the basis of a 
genetic (e.g. sex, ethnicity), demographic (e.g. age35), physiological (e.g. pregnancy, 
menopause) or lifestyle (e.g. level of physical activity,36 diet37) characteristic may be 
pertinent to the scientific substantiation of health claims addressed to a different target 
population (e.g. the general population) when: i) the effect of the food/constituent is also 
observed in subjects who are representative of the target population (e.g. in other studies 
submitted in the application) or ii) if extrapolation of the results from the study group to 
the target population is biologically plausible (i.e. if there are no known scientific reasons 
which could prevent the extrapolation of results from the study group to the target 
population). Biological plausibility will be considered by the NDA Panel on a case-by-case 
basis. 
                                                          
34 Subjects at high risk for disease means individuals with one or more risk factors for a disease who do not meet the diagnostic 
criteria for such disease. 
35 E.g. children, adults, elderly. 
36 E.g. athletes. 
37 E.g. vegetarians, vegans. 
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If it is unclear whether the results from a study group (e.g. diseased patients) could be extrapolated 
to the target population (e.g. if the mechanism of action is unknown), the results from those studies 
could be used as supportive evidence for substantiation only if pertinent efficacy studies in the target 
population are available (see Section 7.4) (EFSA NDA Panel, 2012b). 
The Panel acknowledges that an effect of the food/constituent observed in diseased subjects or in 
subjects at risk of disease may not be necessarily beneficial for, or may not be measurable in, some 
subgroups of the target population (e.g. a decrease in blood cholesterol, blood pressure, postprandial 
blood glucose responses, long-term blood glucose control, endothelial dysfunction). However, the 
Panel considers that certain functions of the body are expected to deteriorate over time as part of the 
ageing process, even in apparently healthy individuals (e.g. blood cholesterol, blood pressure, 
postprandial blood glucose responses, long-term blood glucose control, endothelial function). Thus, 
regular consumption of food/constituent by the target population may contribute to the maintenance 
of such functions for longer periods of time.  
7.7. Scientific evaluation of comparative claims  
Claims for a beneficial effect of the absence (or reduced content) of a food/constituent in a food or 
category of foods are evaluated as comparative claims. Substantiation may be based on evidence for 
an independent role of the food/constituent in an adverse effect. For example, for claims related to a 
reduced content of saturated fatty acids (SFAs) in relation to blood LDL-cholesterol concentrations, 
SFAs have been shown to increase blood LDL-cholesterol concentrations when compared to 
carbohydrates, which have no effect on LDL-cholesterol concentrations, and therefore SFAs have an 
independent role in the adverse effect.  
Claims for a beneficial effect of a food/constituent used to replace a food/constituent with an 
independent role in an adverse effect are also evaluated as comparative claims. Substantiation may be 
based on evidence for an independent role on an adverse effect of the food/constituent which is being 
replaced, together with evidence for the lack of an effect or a reduced effect of the food/constituent 
which is used for replacement. Examples include claims for unsaturated fats and reduced blood LDL-
cholesterol concentrations when replacing saturated fats, for low-fermentable carbohydrates and 
maintenance of tooth mineralisation (‘non-cariogenic’) when replacing fermentable sugars, and for 
low-digestible carbohydrates and reduced postprandial blood glucose when replacing digestible 
carbohydrates. 
Claims related to a comparison between a ‘test’ food and a ‘control’ food (e.g. for changes in appetite 
ratings after food consumption) are also comparative claims. Both the test and the control food should 
be sufficiently characterised for a scientific evaluation with respect to the factors (e.g. energy, volume, 
appearance and taste) which may have an impact on the claimed effect. 
In presenting such claims, applicants should take into account the Commission guidance on the 
implementation of Regulation (EC) No 1924/2006 of December 2007 (Standing Committee on the 
Food Chain and Animal Health, 2007) for the use of comparative claims, including characterisation of 
the appropriate reference or comparator (see also Section 7.1.1). 
7.8. Wordings for health claims evaluated with a favourable outcome  
The NDA considers whether the wording of the claim proposed by the applicant reflects the scientific 
evidence. If not, the NDA Panel proposes a different wording. However, wordings proposed by the 
Panel, although scientifically correct, do not take into account consumer understanding and may not 
be appropriate for consumer communication.38 As explained in Section 4 and Annex A, applicants can 
negotiate with risk managers for alternative wordings during the authorisation process.  
                                                          
38 Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and health 
claims made on foods. OJ L 404, 30.12.2006, p. 9–25. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=
CONSLEG:2006R1924:20100302:EN:PDF 
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7.9. Conditions of use for health claims evaluated with a favourable 
outcome  
For claims based on the essentiality of nutrients, conditions of use are set on the basis that any 
significant amount of the essential nutrient in the diet will contribute to the claimed effect (e.g. 
conditions of use can be linked to nutrition claims). 
For claims other than those based on the essentiality of nutrients, conditions of use are set on the 
basis of the human studies submitted for substantiation by considering the minimum amount of the 
food/constituent (and pattern of consumption, where appropriate), which consistently exerts an effect 
on the function that is mentioned in the claim. In this case, the NDA Panel also considers whether 
such an amount can be reasonably consumed in the context of a balanced diet (e.g. whether the 
consumption of the food/constituent in the amounts required to achieve the claimed effect is realistic 
and unlikely to induce a nutritional imbalance). 
7.10. Extension or modification of the conditions of use for an authorised 
claim  
For the modification or extension of the conditions of use (CoU) of an authorised claim, applications 
can be submitted pursuant to Article 19 of Regulation (EC) No 1924/2006. The request may refer to 
the extension or modification of the authorised CoU with respect to e.g. the formulation of the food 
constituent, the food matrix, the effective dose, the pattern of consumption, the target population or 
the restrictions of use. In order to evaluate whether the CoU for an already authorised health claim 
could be modified, the NDA Panel needs to be assured that the claimed effect assessed in the original 
opinion can also be achieved by the consumption of the food/constituent under the ‘new’ conditions 
proposed by the applicant. The nature and amount of information needed for that purpose may 
depend on the food/constituent, the matrix, the claimed effect, the target population, and the 
proposed mechanisms by which the claimed effect may be achieved (short- and long-term efficacy). 
Examples of Article 19 applications can be found in EFSA published opinions (EFSA NDA Panel, 2010b, 
2014d, 2014e). 
Applications for the modification of an existing authorisation pursuant to Article 19 of Regulation (EC) 
No 1924/2006 should follow the Scientific and technical guidance for the preparation and presentation 
of an application for authorisation of a health claim (EFSA NDA Panel, 2011b). 
8. Scientific aspects to be considered for preparing a health claim 
application 
Before submitting a health claim application, applicants are advised to consider, step-wise, a series of 
issues which are needed for the compilation of applications (Figure 2). 
The first step is to consider whether the claim is based on the essentiality of a nutrient. In this 
context, it is important to reflect on whether the nutrient:  
i. is required for normal human body function(s), i.e. it has an essential mechanistic role in a 
metabolic function and/or it has a unique ability to reverse clinical signs and symptoms of its 
deficiency; 
ii. cannot be synthesized by the body, or cannot be synthesised in amounts which are adequate 
to maintain normal body function(s) in the target population; 
iii. must be obtained from a dietary source. 
If all the above-mentioned conditions are met, the relationship between the consumption of the 
food/constituent and the maintenance of the function (claimed effect) is likely to be established (see 
Section 6.1). However, if the claim is not based on the essentiality of nutrients, human studies on the 
relationship between the consumption of the food/constituent and the claimed effect are required for 
the scientific substantiation of the claim (see Sections 6.2 and 7.4). The remainder of this section 
focuses on how to prepare applications for this type of claims.  
The second step is the characterisation of the food/constituent. The characterisation of essential 
nutrients relates mainly to the chemical form of the nutrient naturally present in foods and forms that 
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are approved for addition to foods.39 For the characterisation of other substances, it is important to 
consider: i) its composition and characteristics, and particularly those characteristics which may 
contribute to or be responsible for the claimed effect. To this end, it is important that applicants have 
good information about the digestion, absorption, metabolism, excretion and/or bioavailability of the 
food/constituent, and an hypothesis/data regarding the mechanism by which the food/constituent 
could exert the claimed effect; ii) the manufacturing process (if applicable), e.g. that the 
food/constituent can be manufactured consistently to the stated specifications and it is stable during 
processing, storage and preparation for consumption (e.g. cooking). 
The third step is the formulation of the claimed effect. To this end, applicants are advised to conduct 
an exploratory review of the human studies available to identify the health/disease outcome(s) which 
have been investigated in relation to the food/constituent and for which the available evidence may 
be strong. Applicants are then advised to reflect on whether the outcome(s) investigated40 may 
describe a beneficial physiological effect41 (claimed effect) in the context of function and/or reduction 
of disease risk claims (see Section 7.2), the extent to which the outcome variable(s)42 used in the 
studies are direct measures of the claimed effect, and whether the methods of assessment43 are 
appropriate.  
The fourth step is to conduct a comprehensive review of (published and unpublished) human studies 
on the relationship between the food/constituent and the health/disease outcome(s) which best 
describe the claimed effect in order to identify all human studies that may be pertinent for 
substantiation. 
It is important to ensure that the studies have investigated food/constituents which comply with the 
specifications provided in the application. If not, applicants should consider changing the specifications 
of the food/constituent for which the claim is requested.44 
If human studies on the relationship between the consumption of the food/constituent and 
health/disease outcome(s) are available, then it is important to consider, for each study, whether or 
not it has been conducted in a suitable study group, i.e. a study group which is representative of the 
target population for the claim or a study group from which extrapolation of the results to the target 
population is biologically plausible.  
If all or some of the studies have been conducted in suitable study groups, then proceed to the next 
step. If extrapolation of the results from the study group to the target population is not biologically 
plausible because the study subjects have a certain disease45 and only studies in patients with this 
disease are available, such studies will not be pertinent to the claim. If extrapolation of the results is 
not biologically plausible because the study subjects belong to a different subgroup of the general 
population46 and no studies in the target subgroup are available, these studies could be pertinent for a 
claim on a different target subgroup. 
The fifth step is to evaluate the quality of each individual human study in relation to:  
                                                          
39  Commission Regulation (EC) No 1170/2009 of 30 November 2009 amending Directive 2002/46/EC of the European 
Parliament and of Council and Regulation (EC) No 1925/2006 of the European Parliament and of the Council as regards the 
lists of vitamin and minerals and their forms that can be added to foods, including food supplements. OJ L 314, 1.12.2009, p. 
36–42. 
40 E.g. coronary heart disease. 
41 E.g. cardiac function. 
42 E.g. fatal myocardial infarction, non-fatal myocardial infarction, sudden death, angina, hear failure. 
43 E.g. self-reported, clinical records, death certificates. 
44 For example, if a claim is requested for a fixed combination of ingredients but all human studies available have investigated 
one of them only and not the fixed combination, applicants should consider to request the claim for the single ingredient 
only; the claim could then be used in a product with the fixed combination of ingredients if it complies with the conditions of 
use for the single ingredient. 
45 Please note that extrapolation of the results obtained in diseased subjects to the target population of the claim may or may 
not be biologically plausible depending on the disease and/or the medications taken by the subjects. A decision on whether 
extrapolation of the results from diseased to non-diseased subjects is biologically plausible is taken by the NDA on a case-by-
case basis upon consideration of the evidence/data/rationale provided by applicants in specific applications to support such 
extrapolation. Providing a complete list of cases in which such extrapolation is/is not biologically plausible is beyond the scope 
of this general scientific guidance. 
46 Please note that extrapolation of the results obtained in subjects from a particular subgroup of the general healthy population 
to another may depend on the claimed effect. Providing a complete list of cases in which such extrapolation is/is not 
biologically plausible is beyond the scope of this general scientific guidance.  
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i) whether the outcome variable(s) are well-defined and appropriate to assess the claimed 
effect, and whether they have been measured using valid methods;47 
ii) the risk of bias.48 
Studies of low quality may not allow conclusions to be drawn for the scientific substantiation of the 
claim, and thus may not be pertinent to the claim (i.e. may not be part of the totality of the evidence).  
The sixth step is to identify studies (in humans, in animals, in vitro) which may be used to develop a 
rationale for the biological plausibility of the claim (e.g. in the context of all that is known about the 
food/constituent and about the claimed effect). These studies include efficacy studies in humans, the 
results of which could not be extrapolated to the target population, efficacy studies in animals, and 
studies on bioavailability and plausible mechanisms of action.  
As a seventh step, applicants are advised to review all the evidence available to them (pertinent 
human studies plus other studies) and make a scientific judgement on whether or not such evidence 
may be appropriate/sufficient for the scientific substantiation of the claim49. If the answer is yes, 
applicants should proceed to the next step. If the answer is no, a careful analysis of the gaps in the 
data available to the applicant can provide an idea of the type and amount of ad hoc research which 
may be needed to fill those gaps, and which may vary widely from application to application (see 
Section 7.3).  
The eighth step is to refine the claimed effect on the basis of the scientific evidence available. 
The ninth step is to define the wording and the conditions of use for the claim, i.e. the dose and 
pattern of consumption of the food/constituent which is required to achieve the claimed effect. The 
wording should reflect the scientific evidence as much as possible, as consumer understanding is not a 
requirement for the scientific assessment. The conditions of use should be defined on the basis of the 
individual human studies used for substantiation and/or meta-analysis of such studies (see Sections 
7.5 and 7.9).  
The tenth and final step is to compile the application, having regard to the scientific and technical 
guidance for the preparation and presentation of an application for authorisation of a health claim 
(EFSA NDA Panel, 2011b). 
Annex A explains in detail the administrative and procedural aspects of applications, from claim 
formulation to authorisation.  
                                                          
47 Applicants are encouraged to consult experts in the particular research field. 
48 Including study design (e.g. randomisation, blinding, control for confounders), statistical analyses, completeness of reporting, 
etc. Different tools to appraise the design and quality of human studies (of different designs) with respect to the risk of bias 
have been developed by different bodies and are publicly available. Although these tools are different from each other, they 
cover a common core of concepts for assessing study quality. As an indication of aspects that the Panel considers when 
appraising the quality of RCTs, see also Appendix B at: http://www.efsa.europa.eu/en/supporting/pub/836e. Applicants are 
also encouraged to consult epidemiologists/biostatisticians for that purpose. 
49  Relevant EFSA guidance documents as well as published opinions on evaluations performed by the NDA Panel on previous 
applications, and particularly those evaluated with a positive outcome, may help applicants to make such judgement. 
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Glossary and Abbreviations  
 
AFLP amplified fragment length polymorphism 
Construct validity The extent to which scores on a particular instrument relate to other measures 
in a manner that is consistent with theoretically derived hypotheses 
concerning the concepts that are being measured 
Content validity The extent to which the concepts of interest are comprehensively represented 
by the items in the questionnaire 
CoU conditions of use 
Criterion validity The extent to which scores on a particular instrument relate to a gold standard 
Disease/disorder A pathological process, acute or chronic, inherited or acquired, of known or 
unknown origin, having a characteristic set of signs and symptoms which are 
used for its diagnosis 
Efficacy study An intervention study (in humans, in animals) which investigates the 
relationship between the food/constituent and the claimed effect 
Essential nutrient A substance required for normal human body function(s) and which cannot be 
synthesized by the body, or cannot be synthesized in amounts which are 
adequate to maintain normal body function(s), and thus must be obtained 
from a dietary source 
Floor and ceiling 
effects 
Lowest or highest possible scores 
Food/constituent A food category, a food or a food constituent (e.g. a nutrient or other 
substance, or a fixed combination of nutrients/other substances) 
Internal 
consistency 
A measure of the extent to which items in a questionnaire (sub)scale are 
correlated (homogeneous), thus measuring the same concept 
Interpretability The degree to which one can assign qualitative meaning to a quantitative 
scores 
ITS internal transcribed spacer 
LUTI lower urinary tract infections 
MLST multilocus sequence typing 
MS Member State 
NDA EFSA Panel on Dietetic Products Nutrition and Allergies 
Pertinent study A study from which scientific conclusions that are relevant to the 
substantiation of a claim (e.g. efficacy studies, bioavailability studies, studies 
on the mechanism(s) by which a food could exert the claimed effect) can be 
drawn 
PFGE pulsed-field gel electrophoresis 
RAPD randomly amplified polymorphic DNA 
Reproducibility The degree to which repeated measurements in stable persons (test-retest) 
provide similar answers 
Responsiveness The ability of a questionnaire to detect clinically important changes over time, 
even if these changes are small 
RFLP restriction fragment length polymorphism analysis 
rRNA ribosomal RNA 
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Study group Individuals recruited for human studies which are submitted for the scientific 
substantiation of a claim 
Suitable study 
group 
A study group which is representative of the target population for the claim or 
a study group from which extrapolation of the results to the target population 
is biologically appropriate 
Supportive 
evidence 
Studies/data which, on their own, are not sufficient for the scientific 
substantiation of a claim and that may be part of the totality of the evidence 
only if pertinent human studies showing an effect of the food/constituent are 
available 
Target population The population group(s) for which health claims are intended (e.g. the general 
healthy population or specific subgroup(s) thereof) 
Totality of the 
evidence 
All the studies (e.g. in humans, in animals, in vitro) which are taken into 
consideration to conclude on the substantiation of a claim (including studies in 
favour and not in favour of the claim) 
UTI urinary tract infection 
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Annex A – Administrative and procedural aspects governing the life cycle 
of a claim application from claim formulation to authorisation  
A.1 Before submitting an application 
A.1.1 Guideline checking 
Applicants who wish to submit an application for authorisation of a health claim under Article 13.5 or 
14 of Regulation (EC) No 1924/2006 or for modification of an existing authorisation pursuant to Article 
19 should read carefully the NDA Panel guidance documents which are published on EFSA’s website:50 
 Scientific and technical guidance for the preparation and presentation of an 
application for authorisation of a health claim, which presents a common format for the 
organisation of the information to assist the applicants for the preparation of a well-structured 
application (i.e. technical dossier) for authorisation of health claims. This guidance outlines:  
 the information and scientific data which must be included in the application;  
 the hierarchy of different types of data and study designs (reflecting the relative strength 
of evidence which may be obtained from different types of studies) and the key issues 
which should be addressed in the application to substantiate the health claim; 
 the number of claims allowed in an application.  
 Specific guidance on the scientific requirements for health claims, which are intended to 
assist applicants in preparing their applications for the authorisation of health claims in specific 
areas, such as those related to:  
 the immune system, the gastrointestinal tract and defence against pathogenic 
microorganisms;  
 antioxidants, oxidative damage and cardiovascular health;  
 appetite ratings, weight management and blood glucose concentrations;  
 bone, joints, skin and oral health;  
 physical performance;  
 functions of the nervous system, including psychological functions.  
These guidance documents present examples drawn from past evaluations to illustrate the approach 
of the NDA Panel in the evaluation of health relationships and outcome variables which may be 
acceptable in these areas, as well as the conditions under which they may be acceptable. A better 
understanding of such an approach could help applicants in preparing applications on health 
relationships and related outcome variables.  
A.1.2 The language and the format required for a claim application 
In order to facilitate the processing of the application (i.e. technical dossier) and make the assessment 
more efficient, applications should preferably be submitted in English. Should the applicant not submit 
the application in English, EFSA will proceed with the English translation. However, it should be noted 
that the responsibility for validating the English translation of the application provided by EFSA rests 
with the applicant. 
Claims applications which adhere to the format of the Scientific and technical guidance for the 
preparation and presentation of an application for authorisation of a health claim (see Section A.1.1) 
must be submitted on a standard electronic medium such as a CD-ROM, DVD or USB key. All 
applications submitted via a Member State to EFSA for evaluation should include the original of a 
signed cover letter with the table of contents.51 
                                                          
50 http://www.efsa.europa.eu/en/nda/ndaguidelines.htm 
51 http://www.efsa.europa.eu/en/press/news/140924.htm   
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A.1.3 Where to submit a claim application? 
Applications for authorisation of health claims pursuant to Articles 14, 13(5) and 19 of the Regulation 
(EC) No 1924/2006 shall be submitted to the National Competent Authority of a Member State in the 
European Union in accordance with Articles 15 and 18, respectively. 
Applicants are invited to check with the recipient Member State on whether the claim falls under the 
scope of Regulation (EC) No 1924/2006 and on the admissibility of the target population for the claim 
at the earliest possible stage before submitting the application (see also Section 4). The National 
Competent Authority will make the valid application and any supplementary information supplied by 
the applicant available to EFSA. 
The list of competent authorities of the Member States within the framework of Regulation (EC) No 
1924/2006 is published on EFSA’s website.52 
A.2 What happens to a claim application upon receipt by EFSA? 
Upon receipt of a claim application via a Member State, EFSA checks the completeness of the 
application.  
The completeness check includes a verification of the administrative compliance as well as the 
elements which are essential to allow a scientific evaluation by the NDA Panel, including clear 
identification of the food/constituent for which the claim is made (consistency throughout the 
application), clear definition of the claimed effect (a defined claimed effect including identification of 
outcome variable(s) and methods of measurement; identification of (a) risk factor(s) for disease risk 
reduction claims), and definition of the conditions of use. If one or more of these elements is missing, 
the NDA Panel may not be able to start the scientific evaluation. In this context, a thorough check of 
the application by EFSA before starting the scientific assessment is essential for minimising the 
number of clock-stops applied during the evaluation process. EFSA aims at providing applicants with 
its first feedback on the completeness check within 30 working days of receipt of the application, 
depending on the size and quality of the application.53 
In the event that EFSA requires additional data, information or clarification in order to consider an 
application complete, the applicant will be asked to supply these data, information or clarifications 
within a notified time limit. EFSA may also communicate with applicants regarding studies which are 
claimed as confidential (see also Section A.4 on EFSA’s handling of confidential and proprietary data). 
Applicants can request a teleconference to clarify a request from EFSA for missing information. 
During the completeness check, EFSA may consult the Commission Services on points of interpretation 
of EU legislation particularly in relation to the scope.   
Once EFSA considers that the application is complete for a scientific evaluation, EFSA sends an 
acceptance letter to the applicant. EFSA makes the application and any supplementary information 
supplied by the applicant available to Member States and the Commission. EFSA publishes relevant 
information for the identification of the application in the Register of Questions, and assigns it an 
official question number. Applicants and stakeholders can follow the status of each application via 
EFSA's Register of Questions. 
The applicant will also be notified of the name of the scientific officer in EFSA in charge of the 
application and related communications with the applicant. All communications between EFSA and the 
applicant during the life cycle of an application is through the assigned scientific officer (not the NDA 
Panel experts).  
A.3 What happens during the evaluation process? 
Once the application is considered complete, the scientific evaluation starts. EFSA shall ensure that 
the Opinion of the NDA Panel is given within 5 months (excluding the stop-the-clock time for the 
applicant to provide answers to questions from EFSA, if needed). 
                                                          
52 http://www.efsa.europa.eu/en/ndaguidance/docs/ndacompetentauthorities.pdf   
53 http://www.efsa.europa.eu/sites/default/files/assets/apdeskapplworkflownutrihealthclaims.pdf  




www.efsa.europa.eu/efsajournal 32 EFSA Journal 2016;14(1):4367 
 
 
A.3.1 When does the stop-the-clock procedure apply? 
During the evaluation, EFSA may request the applicant to provide supplementary information on the 
application (‘stop-the-clock’ procedure). Requests from EFSA to applicants for supplementary 
information are made on the basis of a case-by-case judgement by the NDA Panel or its Working 
Group on Claims in the context of specific applications. 
Based on an analysis of the stop-the-clock letters sent to applicants,54 the issues identified by the NDA 
Panel which have triggered the stop-the-clocks are: clarifications on the studies submitted for 
substantiation (75%); clarifications on the claimed effect and/or the target population (13%); and 
clarifications on the characterisation of the food/constituent for which the claim was proposed (12%). 
Issues related to, for example, the definition of the food/constituent, of the claimed effect, of risk 
factors for disease, or of the conditions of use may only become apparent during the scientific 
assessment of the application by the NDA Panel and not necessarily during the completeness check. 
The NDA Panel may work with the applicants on the reformulation of health claims based on the 
human studies provided for substantiation, if needed.  
Therefore, communication between EFSA and the applicant during this phase is critical for both the 
applicants and the NDA Panel. To this end, upon receipt of EFSA’s letter requesting supplementary 
information, applicants can ask for a teleconference to clarify EFSA’s request, if needed. After 
submitting additional or supplementary information, applicants may be invited by EFSA to attend a 
meeting of an EFSA working group or scientific panel to clarify issues related to the application (i.e. 
Applicants technical hearing). 
The applicant should respond to requests for missing or additional information using electronic 
formats (CD-ROMs, DVDs or USB keys). If the applicant fails to provide the supplementary information 
within the time limit specified by EFSA, the NDA Panel will issue an opinion based on the data 
available to the Panel.  
EFSA applies stop-the-clock timelines in accordance to Regulation (EC) No 1924/2006 and EFSA 
guidance on ‘Indicative timelines for submitting additional or supplementary information to EFSA 
during the risk assessment process of regulated products’.55 
A.3.2 Can a claim application be withdrawn? 
Article 7b of Regulation (EC) No 353/200856 specifies the rules for the withdrawal of applications:  
(1) An application submitted under Article 15 or 18 of Regulation (EC) No 1924/2006 may be 
withdrawn by the applicant up to the moment the Authority adopts its opinion pursuant to Article 
16(1) or Article 18(3) of Regulation No 1924/2006.  
(2) A request for withdrawal of an application must be submitted to the national competent authority 
of a Member State, to which the application was submitted in accordance with Article 15(2) or Article 
18(2) of Regulation (EC) No 1924/2006. 
A.4 How confidential and proprietary data are handled by EFSA?  
Confidential data – In order to comply with its requirements for transparency as outlined in Article 
38 of Regulation (EC) No 178/200257 and Article 16(6) of Regulation (EC) No 1924/2006,58 EFSA has 
to disclose in its published scientific opinions data from dossiers which are considered essential for the 
scientific assessment. To this end, EFSA will take a decision on the confidentiality claims submitted by 
                                                          
54 http://www.efsa.europa.eu/en/events/documents/131120-p03.pdf   
55 http://www.efsa.europa.eu/en/press/news/140414a.htm 
56 Commission Regulation (EC) No 353/2008 of 18 April 2008 establishing implementing rules for applications for authorisation 
of health claims as provided for in Article 15 of Regulation (EC) No 1924/2006 of the European Parliament and of the Council. 
OJ L 109, 19.4.2008, p. 11. 
57 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in 
matters of food safety, as last amended. 
58 Corrigendum to Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on 
nutrition and health claims made on foods (OJ L 404, 30.12.2006), as last amended. 
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the applicant. For example, confidentiality can only be given to specific parts of an unpublished study 
report if duly justified, and not to the entire study. 
It should be noted that, without prejudice to Regulation (EC) No 1049/2001 on public access to 
documents, if a study has not yet been published and its disclosure would undermine the commercial 
interests and rights of the applicant, EFSA will not make such a study available to third parties.  
If the request for confidential treatment for those parts identified by the applicant is accompanied by 
verifiable justification,59 and if this is accepted by EFSA, those elements will be processed by EFSA in a 
confidential manner, and will not be disclosed in the published version of the final scientific opinion. 
EFSA’s decisions on confidentiality are communicated to applicants before the scientific opinion is 
adopted. 
Proprietary data – The decision on granting the protection of proprietary data (e.g. linked to 
requirements for data exclusivity) under Article 21 of Regulation 1924/2006 falls under the 
responsibility of the European Commission when authorising the claims. With respect to the handling, 
use and protection of proprietary data by EFSA, it should be noted that where evidence for 
substantiation includes a request for the protection of proprietary data, the NDA Panel considers in its 
opinion only whether the claim could have been substantiated without the data claimed as proprietary 
by the applicant or not.  
A.5 Adoption and publication of EFSA opinion on claims 
EFSA informs the applicant that EFSA's NDA Panel has adopted a scientific opinion on its application 
one working day after adoption (i.e. Notification email on adoption of scientific output). 
The applicant receives the adopted scientific opinion under embargo one working day before 
publication of the opinion on EFSA's website (i.e. Prenotification of publication). It should be noted 
that, at this stage, a reopening of the scientific evaluation is not possible, and that the applicant is 
consulted only regarding data disclosed in the opinion that EFSA has previously accepted as being 
confidential. 
Following the publication of an adopted scientific opinion, a teleconference with EFSA can be 
requested by the applicant to clarify the rationale for the decision of the NDA Panel and explain the 
evidence and other factors that influenced the outcome (i.e. Teleconference post-adoption). 
A.5.1 Can stakeholders and the public comment on EFSA opinions? 
According to Article 16 of Regulation (EC) No 1924/2006, the applicant or members of the public may 
make comments on EFSA-published scientific opinions. Comments should be sent to the Commission 
within 30 days of publication of the EFSA opinion in question. If considered appropriate, the 
Commission may decide to ask EFSA to address the comments relating to scientific issues. Comments 
are made public by the Commission on its webpage.60 
EFSA responses to the requests received from the Commission are also published on EFSA’s website.61  
A.6 Process for health claim authorisation 
Upon publication of EFSA opinions that have a favourable outcome, any issues related to the final 
wording of health claims including consumer understanding aspects should be addressed to the 
Commission (see Section 4). 
The Commission prepares a draft decision and submits it to the Standing Committee on the Food 
Chain and Animal Health after EFSA publishes its opinion. 
                                                          
59 Precise and factual information, ideally documents, proving that the disclosure of the information requested by the applicant 
to be treated as confidential would result in concrete harm to the commercial or economic interest of the applicant/requestor, 
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After a favourable opinion of the Standing Committee on the Food Chain and Animal Health, the 
European Parliament and the Council have the right of scrutiny on the Commission’s draft decision. If 
there is no objection, the Commission adopts the draft decision. 
In the case of Article 13(5) health claims which have received a favourable EFSA opinion, the Standing 
Committee on the Food Chain and Animal Health is consulted on the Commission's draft decision 
before the Commission adopts it. In this situation, there is no opinion (vote) of the Standing 
Committee and therefore no scrutiny by the European Parliament and the Council. 
Authorised health claims, their conditions of use and applicable restrictions of use, if any, are 
published in the EU Register of claims.62    
  
                                                          
62 http://ec.europa.eu/nuhclaims/  
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Annex B – Characterisation of microorganisms at strain level 
Health claims have been made on microorganisms (e.g. bacteria and yeast). Correct identification of 
the bacterial’s and yeast’s species and strain is of critical importance, as the observed effects in the 
host are species and strain specific, unless the contrary is demonstrated.  
Species identification and sufficient characterisation (genetic typing) at strain level, by using 
internationally accepted molecular methods are needed. In addition, strains should be named 
according to the International Code of Nomenclature.63 It is strongly recommended that strains are 
deposited in an internationally recognised culture collection64 with access number for control 
purposes. 
The Panel’s recommendations have been updated, taking into consideration the current state-of-art 
techniques for identification and molecular characterisation of microorganisms. The Panel also 
indicates that several methods are often needed to be used in combination to obtain the required 
resolution (discriminatory power, reproducibility, etc.) depending on the microorganism in question. It 
should be noted that techniques listed below constitute examples of well-established molecular 
methods for microbial characterisation but these do not constitute an exhaustive list of all existing 
possibilities and that others may result from future advances in the understanding of microbial 
genetics linked to technical developments (see also EFSA BIOHAZ Panel (2013)). 
Characterisation of bacteria (EFSA NDA Panel, 2009b, 2010c) – the Panel suggests the 
following techniques and criteria for characterisation of bacteria which are the subject of health 
claims: 
 Species identification by sequence analysis of robust taxonomic markers including at least two of 
them if needed (e.g. 16S rRNA gene) (Kim et al., 2014) or fully assembled and validated whole-
genome sequence analysis (Goris et al., 2007; Chun and Rainey, 2014) or other internationally 
accepted molecular methods. 
 Strain identification by DNA macrorestriction followed by pulsed-field gel electrophoresis (PFGE), 
multilocus sequence typing (MLST), randomly amplified polymorphic DNA analysis (RAPD), 
amplified fragment length polymorphism (AFLP), whole genome mapping (WGM) or optical 
mapping analysis, fully assembled and validated whole-genome sequence analysis, or other 
internationally accepted genetic typing molecular methods.  
The bacterium is considered to be sufficiently characterised only when these two criteria are fulfilled. 
Characterisation of yeasts (EFSA NDA Panel, 2010c) – The Panel uses the following criteria for 
the characterisation of yeasts which are the subject of health claims: 
 Species identification by sequencing analysis of DNA taxonomic markers (e.g. the D1 and D2 
domains of 26S rDNA or internal transcribed spacer [ITS] regions between the rRNA gene 
subunits, including the 5.8S rRNA gene), restriction fragment length polymorphism analysis 
(RFLP) (e.g. RFLP of the 5.8S rDNA ITS region, RFLP of mitochondrial DNA), fully assembled and 
validated whole-genome sequence analysis or other internationally accepted genetic typing 
molecular methods.  
 Strain identification by chromosome length polymorphism analysis by PFGE, RAPDs, microsatellite 
DNA polymorphism analysis, fully assembled and validated whole-genome sequence analysis or 
other internationally accepted genetic typing molecular techniques. 
Only when these two criteria are fulfilled is the yeast considered to be sufficiently characterised.  
                                                          
63 The approved nomenclature for bacteria is kept at the International Committee on Systematics of Prokaryotes for 
(http://icsp.org/), and the International Code of Nomenclature of fungi is kept by the International Commission on the 
Taxonomy of Fungi (ICTF) (www.fungaltaxonomy.org) and the approved nomenclature for fungi can also be found on the 
MycoBank (http://www.mycobank.org).    
64 http://www.wfcc.info/collections/ 
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In the case of combination of several bacteria and/or yeasts, the Panel considers that if one 
microorganism used in the combination is not sufficiently characterised, the combination proposed is 
not sufficiently characterised. 
The NDA Panel recommends that applicants provide sufficient information complying with the above-
mentioned criteria for the characterisation of microorganisms. 
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Annex C – Considerations on the validation of questionnaires and their 
use as outcome variables for the scientific substantiation of 
health claims. 
Questionnaires are used to assess subject-reported outcomes, which are subjective in nature. They 
may assess an outcome at a single time point or longitudinally over time, e.g. changes from baseline. 
They can be designed to investigate a single concept (e.g. a single symptom) or a combination of 
concepts (e.g. a combination of symptoms relevant for a specific outcome). Whenever objective 
measures are available for an outcome they are generally preferred over the use of subjective 
measures, such as questionnaires. A subjective measurement tool, such as a questionnaire, should 
have been shown to measure reliably the concept or the combination of concepts it intends to 
measure. This approach is not different from any new measurement instruments or novel laboratory 
methods, which have to be validated prior to routine use. 
Questionnaires should have been validated (i.e. should actually measure what they are supposed to 
measure and be suitable for purpose), and should have been shown to be reliable (i.e. are able to 
yield consistent results). For a questionnaire to serve as an acceptable outcome variable for the 
scientific substantiation of a health claim, validation and reliability should ideally have been previously 
and independently established for the study group in the particular study setting. Validating a 
questionnaire in the same study in which the questionnaire is used to measure the outcome variable is 
not appropriate for the purpose of obtaining confirmatory results.  
Several criteria have been developed to assess the measurement properties of questionnaires 
(Aaronson et al., 2002; Terwee et al., 2007), and guidelines on the use of subject-reported outcomes 
are available (FDA (Food and Drug Administration Center for Drug Evaluation and Research (CDER)), 
2009) and provide guidance on how questionnaires could potentially be validated and on how the 
most applicable tool for a certain outcome could be selected.  
Items which have been recommended to be considered when assessing the validity and reliability of a 
given questionnaire in a specific context are (Terwee et al., 2007): (1) content validity, (2) internal 
consistency, (3) criterion validity, (4) construct validity, (5) reproducibility (including agreement and 
reliability), (6) responsiveness, (7) floor and ceiling effects and (8) interpretability (see Glossary). 
These items could be considered by an applicant when determining if a specific questionnaire could be 
considered appropriate in a given context. The NDA Panel notes that, in some cases, it will not be 
possible to assess criterion validity in the absence of a gold standard for measuring the intended 
outcome. However, in cases where such a method is available, criterion validity is an important aspect 
to consider.  
The Panel would like to highlight that particular attention should be paid to the following issues: 
• A questionnaire can only be considered to be appropriate if the population in which the 
questionnaire has been validated is representative of the study population, and if the setting in which 
the questionnaire has been validated is representative of the setting of the study in which it is to be 
used.  
• Any changes made (e.g. modifications of items) to a previously validated questionnaire 
require a revalidation of the questionnaire. 
• Validation is language specific and translating a previously validated questionnaire into 
another language requires further validation steps. 
• A questionnaire which has been validated for a composite score is not necessarily validated 
for the individual constructs which make up the composite score and vice versa. 
• A questionnaire which has been validated to assess an outcome at a single time point may not 
necessarily be validated to assess changes of an outcome over time (responsiveness). 
• A questionnaire which has been validated as an interviewer-administered questionnaire may 
not necessarily be validated in a self-administered setting and vice versa. 
• A questionnaire which has been validated to assess the severity of a condition may not 
necessarily be validated to assess the incidence and vice versa. 
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The Panel wishes to highlight that there is no single correct way to demonstrate the validity of a 
questionnaire. It is a scientific judgement as to the extent to which the information available on 
validation is sufficient to provide confidence in the validity of the results obtained with the 
questionnaire for the particular outcome variable(s) under the study conditions. Also, as the 
appropriateness of a tool will depend on the outcome variable(s) to be measured, the study group, 
the study design and the study setting, no exhaustive list of acceptable questionnaires can be given. 
 
